Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAD-TB
NCT06192160Phase 2Suspended
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Mar 2025
- Primary completion
- Mar 2027
- Countries
- 14
01
Overview
A Phase 2 trial of TBI-223, sutezolid in pulmonary tuberculosis (TB), sponsored by National Institute of Allergy and Infectious Diseases. Started Mar 2025; status: suspended.
02
Drugs
TBI-223sutezolid
03
Conditions
pulmonary tuberculosis (TB)
Beyond the preview
Go deeper on NCT06192160.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06192160.